# A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

> **NCT04094662** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 393 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** Mirogabalin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04094662
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-18
- **Primary completion:** 2022-01-17
- **Final completion:** 2022-01-24
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2022-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094662, "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04094662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*